ClinicalTrials.gg
Enrolling by invitationNCT07050160GRIT-PKP2Updated Nov 12, 2025

Long-term Follow-up Study of Gene Therapy for Arrhythmogenic Cardiomyopathy Due to a Plakophilin-2 Pathogenic Variant

An observational study in Arrhythmogenic Cardiomyopathy, PKP2-ACM and PKP2-ARVC, sponsored by Lexeo Therapeutics. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years to 67 Years. Per ClinicalTrials.gov, last updated 2025-11-12.

Sponsored by Lexeo Therapeutics · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
10
Ages
18 Years to 67 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 231 studies in Cardiomyopathies with a site in United States — 56 open to participants now, 69 under way, 6 of them phase 3. Cardiomyopathies · United States.

Planned enrollment
92nd of 97
10 · median 160
Started
2025
with 10 others
Observational
98 of 231
31 open now
Primary completion
2030-08
later than 56 of 67 live
Registered
216th of 231
by date
Lead sponsor
6 of 231
Lexeo Therapeutics

Among the 231 studies in Cardiomyopathies with a site in United States, this one is the 92nd largest by planned enrollment of the 97 observational ones that give a count, is one of 11 that started in 2025, is one of 98 observational ones, reaches primary completion later than 56 of the 67 other live ones, and was the 216th registered.

Cardiomyopathies

556 studies on the registry are indexed under Cardiomyopathies; 153 are open to participants now.

Browse Cardiomyopathies studies →

Open to participants now

56 of the 231 studies in Cardiomyopathies with a site in United States are open now. Recruiting first, the newest first:

51 more — sign in →

All 56 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 116 Cardiomyopathies studies recruiting now, 70 (60%) set no upper age limit and 18 (16%) stop at 75 or younger; 35 take children under 18; 22 take healthy volunteers.

This study: 18 Years to 67 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 231 studies in Cardiomyopathies with a site in United States, or all of them as a file.
02

Study summary

The primary objective of this Phase 1/2 long-term follow-up (LTFU) study is to assess the long-term safety and tolerability of LX2020 for the treatment of arrhythmogenic cardiomyopathy (ACM) due to a plakophilin-2 gene (PKP2) pathogenic variant (PKP2-ACM).

Read the detailed description

GRIT-PKP2 is a Phase 1/2 long-term follow-up (LTFU) study designed to evaluate the long-term safety and tolerability of LX2020 gene therapy for participants with PKP2-ACM who have previously received LX2020 in the parent study, LX2020-01. After completion of Study LX2020-01, participants will roll over into this study LX2020-02 for an additional 4-year long-term observation. No gene therapy will be administered in Study LX2020-02. Efficacy will be assessed as an exploratory objective.

03

Conditions studied

  • Arrhythmogenic Cardiomyopathy
  • PKP2-ACM
  • PKP2-ARVC

Keywords

  • Arrhythmogenic Cardiomyopathy
  • ACM
  • Cardiomyopathy
  • ARVC
  • Arrhythmogenic Right Ventricular
  • Arrhythmogenic Right Ventricular Dysplasia
  • Genetic cardiomyopathy
  • Gene Therapy
  • PKP2 Gene
  • Plakophilin-2
  • LX2020
  • GRIT-PKP2
  • Ventricular Arrhythmia
  • PVCs
  • Sudden Cardiac Death
  • Cardiac Arrest
04

Who can participate

Ages eligible
18 Years to 67 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants who received LX2020 in Study LX2020-01 will roll over into this study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants who received LX2020 in study LX2020-01

Exclusion criteria

Exclusion Criteria:

  • Concurrent enrollment in any other clinical investigation involving use of an agent.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
10 participants (estimated)
Patient registry
No

Groups and cohorts

  • LX2020 treated participants

    Participants who received LX2020 in Study LX2020-01

06

What researchers measure

Primary outcomes

  1. Percentage of subjects who experienced at least 1 treatment emergent adverse event (TEAE) and/or 1 treatment emergent serious adverse event (TESAE).

    Evaluation of Safety and Tolerability of LX2020

    Time frame: 4 years

Other outcomes

  1. Selected Exploratory

    Change in the frequency of ventricular arrhythmias from baseline.

    Time frame: 4 years

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Aug 2030, 60 months after the start.

Of 141 observational studies under Cardiomyopathies, half reached primary completion within 83 months of starting (the median), counting those still running; a quarter within 34. This study's planned 60 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 11, 2025
First posted
Jul 3, 2025
StartActual
Aug 29, 2025
Primary completionEst.
Aug 2030
CompletionEst.
Aug 2030
Last update
Nov 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07050160
Lead sponsor
Lexeo Therapeutics
Responsible party
Sponsor
First posted
Jul 3, 2025
Start date
Aug 29, 2025
Primary completion
Aug 2030 (estimated)
Completion
Aug 2030 (estimated)
Last update
Nov 12, 2025

Study contacts

Lexeo Clinical Trials
study director · Lexeo Therapeutics

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion